Effect of CGF on Frequency of Alveolar Osteitis Following Partially Erupted Mandibular Third Molar Surgery
Launched by EGE UNIVERSITY · Nov 1, 2019
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
The investigators designed and implemented a randomized single-blind clinical trial.Randomization was performed by simple coin toss to select the side of CGFs fibrin gel placement before the commencement of third molar surgery. In this way, the sides in each patient were randomly divided into 2 study groups:
Group I (test) - with CGFs placed in the extraction socket Group II (control) - without CGFs placement All operations were performed under local anesthesia by the same surgeon. An envelope flap was raised to provide access. Bone removal was done with the help of stainless steel burs. C...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients Age ≥ 18 years of age
- • Willing and able to provide informed consent
- • Ability to cooperate with the requirements of the study protocol
- • Healthy patients without medical diseases or a history of bleeding problems
- • Patients with the need of extraction of third molars
- • The third molars had to be symmetrical, partially-erupted and in the Class I, Level B according to Pell \& Gregory classification and in the vertical angulations according to Winter's classification.
- Exclusion Criteria:
- • Patients who have pre-existing abscess or cellulitis, acute pericoronitis, or pre-existing conditions such as an odontogenic cyst or tumour associated with their third molars
- • Patients who were pregnant and breastfeeding
- • Patients with drug usage such as bisphosphonate, steroids and antidepressants
- • Patients who had a smoking habit
About Ege University
Ege University, a prestigious institution located in Izmir, Turkey, is renowned for its commitment to advancing medical research and education. As a prominent clinical trial sponsor, Ege University leverages its extensive academic resources and expertise in various healthcare fields to facilitate innovative clinical studies. The university is dedicated to enhancing patient care through rigorous research methodologies and collaboration with multidisciplinary teams, ensuring the development of effective therapies and interventions. With a strong focus on ethical standards and regulatory compliance, Ege University aims to contribute significantly to the global medical community by fostering groundbreaking discoveries and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
İzmir, Bornova, Turkey
Patients applied
Trial Officials
Banu Özveri Koyuncu
Study Director
Ege University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials